Long COVID’s heterogenous nature means vast variations in symptoms and severity that may also make it more difficult to study and design good treatment trials. How do you separate strong studies from weak ones, and spot the bunk? Read more from @spichaksimon.bsky.social: bit.ly/4fxNWli
